Evommune, Inc. (EVMN)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Evommune, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 11.30 $ — 1% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 175.6% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.79 | -3.30 – -2.56 | 4 | 75.1% | 8 |
| 12/31/2027 | -3.24 | -4.83 – -2.45 | 1 | -16.1% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.68 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.51 | – | 0 | – | – | -22 | -22 |
| 2025: Q1 | -0.40 | – | 3 | – | -485.20 | -24 | -24 |
| 2025: Q2 | -0.38 | – | – | – | – | -26 | -26 |
| 2025: Q3 | -0.35 | – | 10 | – | -124.80 | -10 | -10 |
| 2025: Q4 | -0.78 | – | 0 | – | – | -17 | -17 |
| 2026: Q1 | -0.60 | – | 0 | -100.00 | – | -28 | -28 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2023 | 5 | -38 | -34 | -1.13 | -30 | -78 | 82 |
| 2024 | 7 | -70 | -67 | -2.22 | -58 | -144 | 76 |
| 2025 | 13 | -81 | -69 | -2.18 | -76 | 206 | 225 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Evommune, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase in den USA.
| Employees | 48 |
|---|---|
| Headquarters | Palo Alto, CA |
| Address | 1891 Page Mill Road, 94304 Palo Alto, United States |
| Phone | (925) 247-4481 |
| Website | evommune.com |
| IPO Date | 6. Nov 2025 |
| ISIN | US30054Y1073 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Luis C. Pena | Founder, President, CEO & Director | 1963 |
| Kyle Carver CPA, M.B.A. | Chief Financial Officer | 1988 |
| Gregory S. Moss Esq. | Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer | 1984 |
| Eugene Andrew Bauer M.D. | Co-Founder, Chief Medical Officer & Director | 1942 |
| Jeegar Patel Ph.D. | Chief Scientific Officer | 1978 |
| Janice Drew M.P.H. | Chief of Development Operations | 1963 |
| Lou Sehl Ph.D. | Senior Vice President of Technical Operations | – |
| Daniel J. Burge M.d. | Senior Vice President of Clinical Development | 1962 |
| J. Mark Jackson M.D. | Senior Vice President of Clinical Development | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 7. Jul 2026 | Kirsch Arthur S | Director | Buy | 10,000 | 13.30 | 133,000 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.